Organization
Alliance for Clinical Trials in Oncology
57 clinical trials
12 abstracts
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.Org: Weill Cornell Medicine, Mount Sinai Hospital-Breast Medical Oncology, Massachusetts General Hospital, UM/Sylvester Comprehensive Cancer Center, UNC Patient Advocates for Research Council,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,
Abstract
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial.Org: Exact Sciences Corporation, Gustave Roussy Cancer Center, Centre Léon Bérard, R&D Unicancer, Alliance for Clinical Trials in Oncology,
Abstract
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.Org: Mayo Clinic, University of California Irvine, UCSF Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Alliance for Clinical Trials in Oncology,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Clinical trial
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line TherapyStatus: , Estimated PCD: 2021-12-01
Clinical trial
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade GliomaStatus: Completed, Estimated PCD: 2019-05-01
Clinical trial
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Molecular and Cytogenetic Monitoring of CML - A Mandatory Companion to CALGB 19804Status: , Estimated PCD: 2001-02-01
Clinical trial
ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse MappingStatus: Active (not recruiting), Estimated PCD: 2025-11-26
Clinical trial
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal WomenStatus: Active (not recruiting), Estimated PCD: 2023-11-10
Clinical trial
Phase I/II Study of BET and MEK Inhibition in Advanced Uveal MelanomaStatus: Withdrawn, Estimated PCD: 2025-07-31
Clinical trial
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDYStatus: Completed, Estimated PCD: 2004-01-01
Clinical trial
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III StudyStatus: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Official Title Neoadjuvant Immunotherapy in Sarcomatoid MesotheliomaStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)Status: Recruiting, Estimated PCD: 2028-06-03
Clinical trial
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-11-08
Clinical trial
Multidrug Resistance Protein Gene Polymorphisms in Acute Myeloid Leukemia. A CALGB Leukemia Tissue Bank ProjectStatus: , Estimated PCD: 2100-01-01
Clinical trial
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/LeukemiaStatus: Completed, Estimated PCD: 2010-09-01
Clinical trial
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2018-11-02
Clinical trial
Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerStatus: Recruiting, Estimated PCD: 2034-08-01
Clinical trial
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)Status: Recruiting, Estimated PCD: 2029-01-15
Clinical trial
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene AlterationsStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid LiposarcomaStatus: Completed, Estimated PCD: 2018-10-04
Clinical trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled TrialStatus: Completed, Estimated PCD: 2021-11-08
Clinical trial
Assessment of Novel Molecular Markers in Acute Myeloid LeukemiaStatus: , Estimated PCD: 2015-12-01
Clinical trial
Genomically-Guided Treatment Trial in Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2038-08-31
Clinical trial
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)Status: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
Phase II Trial of BRAF/MEK Inhibitors in Papillary CraniopharyngiomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III StudyStatus: , Estimated PCD: 2025-08-31
Clinical trial
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and EtoposideStatus: , Estimated PCD: 2022-03-02
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2021-01-04
Clinical trial
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2033-05-31
Clinical trial
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibStatus: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid CancerStatus: Completed, Estimated PCD: 2019-02-27
Clinical trial
An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated NeuropathyStatus: Recruiting, Estimated PCD: 2030-05-31
Clinical trial
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway MutationsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women With Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial DiagnosisStatus: Completed, Estimated PCD: 2012-11-01
Clinical trial
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline MutationStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALLStatus: , Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation TherapyStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2028-05-01
Clinical trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC TrialStatus: Terminated, Estimated PCD: 2021-12-13
Clinical trial
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain MetastasesStatus: Terminated, Estimated PCD: 2019-02-01
Clinical trial
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal CancerStatus: Completed, Estimated PCD: 2015-11-01
Clinical trial
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2018-10-02
Clinical trial
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)Status: Terminated, Estimated PCD: 2017-04-03
Clinical trial
Official Title A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated LiposarcomaStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated AnorexiaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)Status: Completed, Estimated PCD: 2016-01-01
Clinical trial
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade GliomaStatus: Recruiting, Estimated PCD: 2025-10-01
Abstract
Impact of a web-based decision aid on socioeconomically disadvantaged patients’ engagement in decision making (Alliance A231701CD).Org: Bay Area Tumor Institute, Mayo Clinic, Carle Cancer Center, Alliance for Clinical Trials in Oncology,
Abstract
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.Org: Northwestern University Robert H. Lurie Comprehensive Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center,
Abstract
Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD).Org: MD Anderson Cancer Center, Alliance Statistics and Data Management Center, Mayo Clinic, American College of Surgeons, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
From the lab to the clinic: Lessons learned from a translational working group.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Durham, NC, COMET Study Patient Leadership Team, San Francisco, CA,